SignalSilence® p21 Waf1/Cip1 siRNA I #6456
Product Specifications
| REACTIVITY | H |
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
CST recommends transfection with 100 nM SignalSilence® p21 Waf1/Cip1 siRNA I 48 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Storage
SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.
Product Description
SignalSilence® p21 Waf1/Cip1 siRNA (Human Specific) allows the researcher to specifically inhibit p21 Waf1/Cip1 expression using RNA interference, a method in which gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from Cell Signaling Technology are rigorously tested in-house and have been shown to reduce protein expression in specified cell lines.
Background
The tumor suppressor protein p21 Waf1/Cip1 acts as an inhibitor of cell cycle progression. It functions in stoichiometric relationships forming heterotrimeric complexes with cyclins and cyclin-dependent kinases. In association with CDK2 complexes, it serves to inhibit kinase activity and block progression through G1/S (1). However, p21 may also enhance assembly and activity in complexes of CDK4 or CDK6 and cyclin D (2). The carboxy-terminal region of p21 is sufficient to bind and inhibit PCNA, a subunit of DNA polymerase, and may coordinate DNA replication with cell cycle progression (3). Upon UV damage or during cell cycle stages when cdc2/cyclin B or CDK2/cyclin A are active, p53 is phosphorylated and upregulates p21 transcription via a p53-responsive element (4). Protein levels of p21 are downregulated through ubiquitination and proteasomal degradation (5).
RNA interference has been used to silence p21 Cip1 expression in human endothelial cells, preventing TNF-alpha mediated growth inhibition (6).
RNA interference has been used to silence p21 Cip1 expression in human endothelial cells, preventing TNF-alpha mediated growth inhibition (6).
- Pestell, R.G. et al. (1999) Endocrine Rev. 20, 501-34.
- Cheng, J. et al. (1999) EMBO J. 18, 1571-83.
- Flores-Rozas, H. et al. (1994) Proc. Natl. Acad. Sci. USA 91, 8655-9.
- Wang, Y. and Prives, C. (1995) Nature 376, 88-91.
- Sheaff, R.J. et al. (2000) Cell 5, 403-10.
- Basile, J.R. et al. (2003) Mol Cancer Res 1, 262-70.
Alternate Names
CAP20; CDK-interacting protein 1; CDKN1; CDKN1A; CIP1; MDA-6; MDA6; Melanoma differentiation associated protein; Melanoma differentiation associated protein 6; p21; PIC1; SDI1; WAF1
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not for Use in Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
SignalSilence is a registered trademark of Cell Signaling Technology, Inc.
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.